Skip to main content
. 2015 Oct 14;8(49):86799–86815. doi: 10.18632/oncotarget.5717

Figure 6. Rak deficiency confers increased vulnerability to DNA damaging agents and PARP inhibitors.

Figure 6

A. MCF10A cells were transfected with shRNAs targeting control or Rak and underwent puromycin selection for 3–4 weeks. Cells were subjected to western blot analysis with an anti-Rak antibody. B. Cells were plated at various densities in 6-well plate, irradiated at 0, 2, 4, 6, 8 or 10 Gy and subjected to clonogenic survival assays. Cells were treated with C. Cisplatin or D. PARP inhibitor AZD2281, and subjected to MTT assays. Result represents the mean ± SD of at least three independent experiments. *p < 0.05; **p < 0.01; ***p < 0.005.